Geron Corporation (GERN)
NASDAQ: GERN · Real-Time Price · USD
1.950
+0.180 (10.17%)
At close: Feb 24, 2026, 4:00 PM EST
1.944
-0.006 (-0.33%)
After-hours: Feb 24, 2026, 7:59 PM EST
Geron Employees
Geron had 229 employees as of December 31, 2024. The number of employees increased by 88 or 62.41% compared to the previous year.
Employees
229
Change (1Y)
88
Growth (1Y)
62.41%
Revenue / Employee
$800,886
Profits / Employee
-$349,301
Market Cap
1.24B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 229 | 88 | 62.41% | 229 | 0 |
| Dec 31, 2023 | 141 | 34 | 31.78% | 141 | 0 |
| Dec 31, 2022 | 107 | 35 | 48.61% | 107 | 0 |
| Dec 31, 2021 | 72 | 17 | 30.91% | 69 | 3 |
| Dec 31, 2020 | 55 | 9 | 19.57% | 53 | 2 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 838 |
| Pharming Group | 404 |
| Xeris Biopharma Holdings | 394 |
| Sana Biotechnology | 194 |
| Day One Biopharmaceuticals | 184 |
| Inhibrx Biosciences | 161 |
| ORIC Pharmaceuticals | 106 |
| Nanobiotix | 103 |
GERN News
- 1 day ago - Geron Plans to Present at Upcoming Investor Conferences - GlobeNewsWire
- 6 days ago - Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 days ago - Top 3 Health Care Stocks That May Collapse This Quarter - Benzinga
- 13 days ago - Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - GlobeNewsWire
- 27 days ago - Geron: Underpromise And Overdeliver Could Be The 2026 Strategy (Rating Upgrade) - Seeking Alpha
- 6 weeks ago - Geron Corporation Provides 2026 Financial Guidance - GlobeNewsWire
- 2 months ago - Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation - GlobeNewsWire
- 2 months ago - Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS - GlobeNewsWire